Conférence de la 8ème édition du Breaking of the wall : role of allergy and histamine release. Cours international « Atelier Paludisme » - JAMBOU Ronan
Guide pour le suivi et l'évaluation des programmes - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Luciano TUSEO - World Health Organization / Roll Back Malaria - Office for Madagascar and Reunion - Antananarivo, Madagascar - maloms@iris.mg
Monitoring and Evaluation Toolkit - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Luciano TUSEO - World Health Organization / Roll Back Malaria - Office for Madagascar and Reunion - Antananarivo, Madagascar - maloms@iris.mg
Développement nouveaux médicaments - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Pascal MILLET - Université Victor Segalen Bordeaux2, France - pascal.millet@u-bordeaux2.fr
Diagnostic biologique du paludisme - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Didier MENARD et Vincent THONIER
Guide d’élaboration d’un plan de gestion des achats et des stocks (Global Funds) – (Version C) - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
Guide d’élaboration d’un plan de gestion des achats et des stocks (Global Funds) – (Version A) - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
PharmacoVigilance & Supply - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
Guide d’élaboration d’un plan de gestion des achats et des stocks (Global Funds) – (Version B) - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
Réponse immunitaite et anémie sévère - Présentation de la 5e édition du Cours international « Atelier Paludisme » - Abdalli Mari MOUHAMADI - Médecin - Ministère de la Santé / PNLP - Moroni, Union des Comores - internetshop2006@yahoo.fr
Pharmacopée traditionnelle et paludisme - Conférence de la 5e édition du Cours international « Atelier Paludisme » - Michel RATSIMBASON - Centre National des Recherches Pharmaceutiques (CNARP), Madagascar - mratsimbason@yahoo.com
Les suivis de cohorte dans l’étude du paludisme : place dans les études épidémiologiques et exemples comparés - Conférence de la 5e édition du Cours international « Atelier Paludisme » - Laurence MARRAMA - Institut Pasteur de Guadeloupe - lmarrama@pasteur-guadeloupe.fr
Polymorphisme parasitaire et accès graves en zone périurbaine - Conférence de la 5e édition du Cours international « Atelier Paludisme » - Ronan JAMBOU - Institut Pasteur de Dakar - rjambou@pasteur.sn
Guide pour le suivi et l'évaluation des programmes - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Luciano TUSEO - World Health Organization / Roll Back Malaria - Office for Madagascar and Reunion - Antananarivo, Madagascar - maloms@iris.mg
Monitoring and Evaluation Toolkit - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Luciano TUSEO - World Health Organization / Roll Back Malaria - Office for Madagascar and Reunion - Antananarivo, Madagascar - maloms@iris.mg
Développement nouveaux médicaments - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Pascal MILLET - Université Victor Segalen Bordeaux2, France - pascal.millet@u-bordeaux2.fr
Diagnostic biologique du paludisme - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - Didier MENARD et Vincent THONIER
Guide d’élaboration d’un plan de gestion des achats et des stocks (Global Funds) – (Version C) - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
Guide d’élaboration d’un plan de gestion des achats et des stocks (Global Funds) – (Version A) - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
PharmacoVigilance & Supply - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
Guide d’élaboration d’un plan de gestion des achats et des stocks (Global Funds) – (Version B) - Séances Pratiques de la 5e édition du Cours international « Atelier Paludisme » - René CAZETIEN - Sanofi Aventis, Gentilly, France - rene.cazetien@sanofi-aventis.com
Réponse immunitaite et anémie sévère - Présentation de la 5e édition du Cours international « Atelier Paludisme » - Abdalli Mari MOUHAMADI - Médecin - Ministère de la Santé / PNLP - Moroni, Union des Comores - internetshop2006@yahoo.fr
Pharmacopée traditionnelle et paludisme - Conférence de la 5e édition du Cours international « Atelier Paludisme » - Michel RATSIMBASON - Centre National des Recherches Pharmaceutiques (CNARP), Madagascar - mratsimbason@yahoo.com
Les suivis de cohorte dans l’étude du paludisme : place dans les études épidémiologiques et exemples comparés - Conférence de la 5e édition du Cours international « Atelier Paludisme » - Laurence MARRAMA - Institut Pasteur de Guadeloupe - lmarrama@pasteur-guadeloupe.fr
Polymorphisme parasitaire et accès graves en zone périurbaine - Conférence de la 5e édition du Cours international « Atelier Paludisme » - Ronan JAMBOU - Institut Pasteur de Dakar - rjambou@pasteur.sn
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
Breaking of the wall : role of allergy and histamine release
1. Breaking of the wall : role of allergy and
histamine release
Ronan Jambou MD, PhD
Immunology Unit
Institut Pasteur de Madagascar
Vascular
Immunology
Unit
2. Expected decrease of Rural Malaria transmission
Kilifi _ Kenya Malaria J 2007
Kilifi _ Kenya Malaria J 2007 Swaziland WHO Report 2006
Swaziland WHO Report 2006
3. Changes in transmission modulate Malaria profil
Total Nb of attacks 60 % within
years old adluts
6
Danané, Côte d'Ivoire: ≥ 300 b.i.a./human/year 25 10%
Dielmo, Sénégal: 100-300 b.i.a./human/year 43 23%
5
Ndiop, Sénégal: 10-30 b.i.a./human/year 62 41%
A n n u a l N b o f m a l a r i a a tt a c k s
4 Pikine, Sénégal: ≤1 b.i.a./human/year 25 50%
Saharevo, Madagascar: ≤1 b.i.a./human/year 32 53%
3
2
1
0
0 5 10 15 20 25 30 35 40 45 50 60
Age (years)
Kilifi _ East Africa Mwangi et al JID 2005
Kilifi _ East Africa Mwangi et al JID 2005 West Africa // Madagascar (meta-analysis)
West Africa Madagascar (meta-analysis)
No clear change in mortality
7. Histamine can modulate endothelial and immune cells functions
Allergy / helminths IgE Antigen
platelets / neutrophils basophiles HRF/TCTP
Histamine
( HR1, HR2, HR3, HR4, HR5 )
cytokine network (IL4, IL2..) vascular permeability DC response to TH2 type
eicosanoid pathway production of IgE
endothelial cells response Platelet + IRBC
to inflammation
vWF adhesion
Cerebral malaria ??
8. PfTCTP is expressed by late trophozoites
Timing genes 40
35 gene T8h Pf TCTP
30
gene T12h
25
- 38% identity, 53%
20
15 similarity with hTCTP
10
5 - mimics hTCTP in vitro
0
P0 P6 P12 P18 P24 P30 P36 P42 P48 on histamine release
Sampling time - 0.1 to 1µg/ml in serum
from patients with
malaria
4,5
Transcript RQ
4
3,5
- totally conserved in 350
PFTCTP
3 P falciparum field
2,5
2
isolates => target human
1,5 cells ??
1
0,5
2 8 14 20 26 32 38 44 50 hours
Parasite cycle time Plasmo-DB
- synchronisation + sampling every 6h over 54h = « sampling time »
- use of thin smear and timing genes (P David) to define the « parasite time » (gene
8h= MAL8P1.4, gene 12h=PFI1735c
- normalisation of mRNA on average of (N1= PFC0255c and N2=PFA0570), then at
time with less mRNA (T44 = 1 for PfTCTP)
10. Area of Dakar
Gouly Couly
Seasonal 17°
W 16° 15° 14° 13° 12°
transmission 16°
N
15°
4 M inhabitants Dakar
= 1/3 Senegal SENEGAL
14°
3.5% territory 13°
An arabiensis
11. Longitudinal study: Gouly couly
Enrolment End
Jun 04 Jun 06
july 04 Nov. 04 Jun 05
IgE Baso, IgE Baso, IgE
dry season Rainy season dry season Rainy season dry season
Drug resistance study
Follow up
13. IgE responses : Gouly couly
100
10 1,5 Low
80
IgE ug/mL
8
1
60
6
40 0,5
4
2 20 0
0 july 04 Nov 04 July 05
0
9-19 20-39 40-80 9-19 20-39 40-80
2,5 medium
Total IgE ug/L % of subjects with > 0.4µg/l 2
IgE ug/mL
1,5
No difference 1
nov_04 according to age for
45 Jun_05 0,5
40
high IgE level
0
35
% IgE_Pf positive
30 Stability of IgE level
25
« High is high » 30
high
20
25
IgE ug/mL
15
20
10 No change in [IgE]
5 15
0
according to season 10
9-19 20-39 40-80 5
Higher percent of 0
% of subjects with IgE-Pf 1 2 3
Pf-IgE during dry
season
14. Basophiles responses : Gouly couly
standard antigens
nov jun
90
Percent responders
80 flmp
70 D farinae
60 D pteronyssinus
50 Percent of responders
40 maximum during rainy
30
20
season
10
0 Pf can induce response
9-19y 20-39y 40-80y for 10% of villagers
during rainy season
80 nov jun nov jun nov jun
High response for
70
Pf antigens salivary glands
Percent responders
Hemozoin
60
Pf ghost
50 Salivary glands
40
30
Mosquitoes can
20
trigger basophiles
10
activation
0
9-19y 20-39y 40-80y
16. Basophiles responses IgE responses
Percent of responders No difference
maximum during rainy according to age for
season high IgE level
Pf can induce response Stability of IgE level
for 10% of villagers « High is high »
during rainy season
Higher percent of
High response for Pf-IgE during dry
salivary glands season
Mosquitoes can Anti-IgE present
trigger basophiles “consummed” ?
activation
Players are there !
18. Area of Dakar
Patients
Severe malaria (SM) cases were recruited at the Intensive Care Unit (CHNU)
Mild malaria (MM) matched cases were recruited at the Saint-Martin Dispensary
Healthy matched subjects attending the laboratory for routine examination
19. Basal level of CD203c expression
Mild malaria have = lower basal level of CD203c expression
20. IgE independant activation of basophiles
HZ hemozoin (malaria pigment)
Cerebral malaria = higher reactivity to IgE-independent stimulation
21. A
Severe malaria
=
higher reactivity to
IgE-dependent
stimulation
B +
No over-stimulation
25. Pf-TCTP / anti Pf-TCTP
Cerebral malaria = higher level of Pf-TCTP
ELISA with Pf-specific
monoclonal antibodies
(horizontal lines represent median for positive individuals only)
26. PfTCTP in serum and response to anti-IgE
Stimulation with anti-IgE 0 (PBS), 0.1, 1 or 10 µg/mL
Presence of PfTCTP is associated with higher IgE dependant response
27. Anti-PfTCTP in serum and response to IgE
Presence of anti-PfTCTP is associated with protection against
excessive IgE dependant response
28. Summary
Cerebral malaria is associated with higher basophile
response to both IgE independent and dependant
response, without overstimulation
rPf-TCTP enhances basophile response during CM and
induces overstimulation in healthy subjects
Presence of PfTCTP in serum enhances IgE dependant
response; presence of anti-Pf-TCTP decreases this
response.
Allergic response is enhanced during CM
Relevant with higher histamine detection
29. Histamine and brain endothelial cell interaction
« to treat or not to treat »
37. Histamine increases VCAM but not ICAM expression
18
Histamine 100µM, 10µM, 1µM
16
Percent of positive cells*
Cimetidine 20µM,
14 diphenylhydramine 20µM,
12
10
8
6
4
2
0
Histamine100 Histamine100 Histamine_10 Histamine_1 control
+ antiH1H2 *Flow cytometry analysis after trypsinization of the HBEC-D3
Anti H1/H2 inhibits histamine effect on VCAM1 expression
38. The murine model of CM
Score Observation
0 No discernible clinical signs
neurological
phase 1 Hunched posture, slightly
hyperparasitaemia
ruffled fur
0 7 14 21
days 2 Very ruffled fur, incipient
severe motor impairment
cerebral anaemia
malaria 3 Very ruffled fur, severe
motor impairment such
as ataxia, hemiplegia
Blood collected and paraplegia,
convulsions, fitting and
Platelet-free plasma the Wooley white sign
(CBA only).
4 Very little movement, cold
to the touch
39. Anti_H1 increases survival of P berghei infected mice
100
Percent survival
Control
75 Citicholine
Diphenyhydramine (anti-H1)
50
25
0
0 7 14
Day post-PbA infection
Day post-PbA
Control Citicoline DPH
infection
5.
6. 4 2
7. 3 2 4
8. 2 1
9. 3
Beghdadi et al 2008
40. Conclusion
Allergy : 20% of population with high IgE level = stable
Seasonal variation of basophiles activation
=> Impact of mosquitoes bites on histamine release
Cerebral malaria is associated with hyper reactivity of
basophiles , without auto-regulation
PfTCTP enhances / anti-TCTP decrease, this response
Rapid opening of intercellular junction thru H1R
Anti-H1 can inhibit this effect
Anti-histamine = can improve the treatment of CM ?
Clinical trial
41. University Sydney
V Combes
A Sanchez Perez
Institut Pasteur de
Dakar F Elassaad
D Aldebert MJ Jambou
GE. Grau Institut Pasteur de
S Pelleau
Madagascar
L Marrama
Romy
F Diène-Sarr
Tsiry
R Paul Emma
Ibrahima Dia IMTSSA- Le Pharo
B Diop S Pelleau
JC Moreau D Parzy
Institut Pasteur
(PF5)
F Nato, P Beguin
43. IFNg / IL10 balance
A B C
IFNg IL10 IFN/IL10
Severe malaria = imbalanced pro/anti-inflammatory response
44. Histamine release and HRFs
TCTP
- found in all eukaryotes , with two conserved motifs (microtubules binding domain)
- control cells proliferation, division, and apoptose => overexpression in cancer
Human TCTP (IgE-dependent HRF)
-Gene locus 13q12-q14
- induces histamine release by basophiles of atopic patients
- in vitro : increase reactivity of basophiles to other stimulus (IgE, ..etc)
- induce proliferation of B cells and activation of eosinophiles
Pf TCTP
- 38% identity, 53% similarity with hTCTP
- mimics hTCTP in vitro on histamine release
- 0.1 to 1µg/ml in serum from patients with malaria
- totally conserved in 350 P falciparum field isolates => target human cells ??
Induction of idiopathic allergy ?
45. PfTCTP down regulates expresion of TRL2 and Vcam1 in HMEC
60 8h of stimulation
Relative
quantity
20
6
2
1
-5
ICAM-1 IL-6 TNFb TLR-2 VCAM-1
IL-1b IL-8
Moderate direct effect of recombinant PfTCTP on endothelial cells
- Vcam and TRL2 repression
- no effect on permeability
- no effect on microparticules productions
47. Severe Malaria
Newborn
fever
dehydration Adult
convulsion Respiratory distress
Metabolic disorders cerebral malaria
= impaired consciousness low parasiteamia
= delay in treatment
Child
Severe anaemia +++
High parasitaemia +++
Cerebral pathology
48. From rural to urban: trends of the population
85 82
76 74
61
54 55
53
47
42
37 37
29
15 17
Monde Afrique Asie Amérique Régions plus
latine/Caraïbes avancées
1950 2000 2030 (projections)
Source : Nations Unies, Perspectives de la population dans le monde, Edition 2003 (scénario moyen), 2004.
49. From children to adults
0,3
0,4
0-1 y
0,25 0,35 1- 4 y
0,2
0,3 5-14 y
0,25 15- 49 y
0,15
0,2 > 50 y
0,1 0,15
0,05
0,1
0,05
0
septembre octobre novembre decembre
0
sept oct nov dec
Prevalence of malaria in consultations
prevalence of severe malaria.
1400
0,6
1200
0,5 1000
0,4 800
0,3 600
0,2 400
0,1 200
0 0
septembre octobre novembre decembre M F M F M F M F M F
0-1 an 1- 4ans 5-14 ans 15- 49 ans 50ans &+
part of class of age in the malaria cases
consultations by age
Changes of risks Changes in control strategies
Major challenge for the next 10 years
50. TNF plays a major role in sequestration
sol
or
PRBC binding
mem mem
TNF LT ICAM-1
ICAM- monocyte binding
upregulation
platelet binding
TNFR2
brain endothelial cells
Functional consequence of TNFR2 upregulation (mouse model, PbA infection)
Lucas et al., Eur J Immunol 27: 1719, 1997
Lou, Lucas & Grau Clin Microbiol Rev 14: 810, 2001
Stoelcker et al., Infect Immun 70: 5857, 2002